We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Molecular Tests Available for Multiple STIs

By LabMedica International staff writers
Posted on 31 Jul 2018
Mycoplasma genitalium (MG) is a sexually transmitted, small and pathogenic bacterium that lives on the ciliated epithelial cells of the urinary and genital tracts in humans. More...
It is spread through unprotected intercourse and is now becoming resistant to antibiotics.

MG can present similar symptoms to chlamydia, which is the most common sexually transmitted infections (STI) in Australia, including a burning sensation when urinating and pain or bleeding during and after intercourse. Males may experience watery discharge from their penis. However, many patients are asymptomatic and do not know they are infected.

Most laboratories routinely test for chlamydia and gonorrhea, the two most pathogenic STIs, however Mycoplasma, Trichomonas and Ureaplasma are also STI infections, which can have health implications. AusDiagnostics (Mascot, Australia) a leading commercial supplier of highly multiplexed diagnostics to microbiology laboratories, currently sells a molecular test kit for all five STIs and is adding the common resistance genes found in Mycoplasma and gonorrhea in a new kit being validated at a hospital in Melbourne.

In a study performed at the hospital in Australia, samples that had previously been analyzed for chlamydia and gonorrhea were re-analyzed on the AusDiagnostics test kit. Three out of 72 were found to contain Mycoplasma genitalium and seven contained Ureaplasma urealyticum. This means that the traditional testing missed 14% of the STIs. Although the jury is still out on the severity of Ureaplasma in STI infections, this is still useful information for the treating doctor. In another study, four Trichomonas positives were found in 200 samples that had previously been declared free of STIs using tests that only measured chlamydia and gonorrhea.

Keith Stanley PhD, a professor and AusDiagnostics Managing Director, said, “It is important for doctors to test for a range of STIs to ensure that patients are treated for infections as early as possible. The advantage of a multiplex approach is that all the STI organisms and their resistance can be measured at one time from one sample instead of having to request a second test for resistance once a positive is found. This simplifies the laboratory work flow and reduces the chance of missing an important infection.”

Related Links:
AusDiagnostics


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.